Antimelanoma Differentiation-associated Gene 5 Dermatomyositis

REFERENCES

1. 1.↵
   1. Fiorentino D,
   2. Chung L,
   3. Zwerner J,
   4. Rosen A,
   5. Casciola-Rosen L

   . The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011;65:25–34.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Moghadam-Kia S,
   2. Oddis CV,
   3. Sato S,
   4. Kuwana M,
   5. Aggarwal R

   . Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 2016;68:689–94.

   OpenUrlCrossRef
3. 3.↵
   1. Chen Z,
   2. Cao M,
   3. Plana MN,
   4. Liang J,
   5. Cai H,
   6. Kuwana M,
   7. et al.

   Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res 2013;65:1316–24.

   OpenUrlCrossRef
4. 4.↵
   1. Hamaguchi Y,
   2. Kuwana M,
   3. Hoshino K,
   4. Hasegawa M,
   5. Kaji K,
   6. Matsushita T,
   7. et al.

   Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011;147:391–8.

   OpenUrlCrossRefPubMed